Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure

Schizophrenia Research

Volumn 58, Issue 2-3, 2002, Pages 313-321

  Bustillo, Juan R ^a   Lauriello, John ^a   Rowland, Laura M ^a   Thomson, Lisa M ^a   Petropoulos, Helen ^a   Hammond, Roger ^a   Hart, Blaine ^b   Brooks, William M ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

1H MRS; Antipsychotic drug; Disease progression; Frontal lobe; Schizophrenia

Indexed keywords

HALOPERIDOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; PROTON; QUETIAPINE;

ADULT; ARTICLE; BRAIN REGION; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EXPOSURE; FOLLOW UP; HUMAN; NEUROCHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHIATRIC TREATMENT; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OCCIPITAL LOBE; PREFRONTAL CORTEX; SCHIZOPHRENIA;

EID: 0036888751     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00210-4     Document Type: Article

References (47)

1. Baldessarini R.J., Hegarty J.D., Bird E.D., Benes F.M. Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Am. J. Psychiatry. 154:1997;861-863.
2. Barker P.B., Soher B.J., Blackband S.J., Chatham J.C., Mathews V.P., Bryan R.N. Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration standard. NMR Biomed. 6:1993;89-94.
3. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 154:1989;672-676.
4. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., Neufeld R.W.J. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 54:1997;959-965.
5. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T.W., Frank J.A., Tedeschi G., Weinberger D.R. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopy imaging. Am. J. Psychiatry. 153:1996;1554-1563.
6. Bertolino A., Callicott J.H., Mattay V.S., Weidenhammer K.M., Rakow R., Egan M.F., Weinberger D.R. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry. 49:2001;39-46.
7. 1H-MRS differentiates white matter hyperintensities in subcortical arteriosclerotic encephalopathy from those in normal elderly. Stroke. 28:1997;1940-1943.
8. 1H-MRS in vivo. Magn. Reson. Med. 40:1999;193-197.
9. Brooks W.M., Jung R.E., Ford C.C., Greinel E.J., Sibbitt W.L. Jr. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J. Rheumatol. 26:1999;81-85.
10. Buchsbaum M.S., Potkin S.G., Siegel B.V., Lohr J., Katz M., Gottschalk L.A., Gulasekaram B., Marshall J.F., Lottenberg S., Teng C.Y. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch. Gen. Psychiatry. 49(12):1992;966-974.
11. 1H-Magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol. Psychiatry. 36:1994;792-800.
12. Bustillo J.R., Lauriello J., Rowland L.M., Jung R.E., Petropoulos H., Hart B.L., Blanchard J., Keith S., Brooks W.M. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res.: Neuroimaging. 107:2001;135-149.
13. Cecil K.M., Lenkinski R.E., Gur R.E., Gur R.C. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naïve patients with schizophrenia. Neuropsychopharmacology. 20:1999;131-140.
14. Chakos M., Lieberman J., Bilder R., Borenstein M., Lerner G., Bogerts B., Houwei W., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiatry. 151:1994;1430-1436.
15. Choe B., Kim K., Suh T., Lee C., Paik I., Bahk Y., Shinn K., Lenkinski R. H-magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naïve, chronic schizophrenia. Acad. Radiol. 1:1994;211-216.
16. Choe B.Y., Suh T.S., Shinn K.S., Lee C.W., Lee C., Paik I.H. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest. Radiol. 6:1996;345-352.
17. Deicken R.F., Zhou L., Corwin F., Vinogradov S., Weiner M.W. Decreased left frontal lobe N-acetylaspartate in schizophrenia. Am. J. Psychiatry. 154:1997;688-690.
18. DeLisi L.E., Sakuma M., Tew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res.: Neuroimaging. 74:1997;129-140.
19. Ende G., Braus D.F., Walter S., Weber-Fahr W., Soher B., Mauldsley A., Henn F.A. Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr. Res. 41:2000;389-395.
20. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W. 1995a. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research.
21. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W. 1995b. Structured Clinical Interview for DSM-IV Axis I Disorders, Non-Patient Edition (SCID-NP), version 2. New York, New York, New York State Psychiatric Institute, Biometrics Research.
22. Friedman S.D., Stidley C.A., Brooks W.M., Hart B.L., Sibbitt W.L. Jr. Brain injury and neurometabolic abnormalities in systemic lupus erythematosus. Radiology. 209:1998;79-84.
23. Fukuzako H., Takeuchi K., Hokazono Y., Fukuzako T., Yamada K., Hashiguchi T., Obo Y., Ueyama K., Takigawa M., Fujimoto T. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Res.: Neuroimaging. 16:1995;193-200.
24. Gur R.E., Cowell P., Turetsky B.I., Gallagher F., Cannon T., Bilker W., Gur R.C. A follow-up magnetic resonance imaging study of schizophrenia. Arch. Gen. Psychiatry. 55:1998;145-152.
25. Guy W. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. 1976;534-537 US Department of Health, Education and Welfare, Washington, DC.
26. Heimberg C., Komoroski R.A., Lawson W.B., Cardwell D., Karson C.N. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res.: Neuroimaging. 83:1998;105-115.
27. Holcomb H.H., Cascella N.G., Thaker G.K., Medoff D.R., Dannals R.F., Tamminga C.A. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry. 153:1996;41-49.
28. Jung R.E., Yeo R.A., Chiulli S.J., Sibbitt W.L. Jr., Weers D.C., Hart B.L., Brooks W.M. Biochemical markers of cognition: a proton MR spectroscopy study of normal human brain. NeuroReport. 10:1999;3327-3331.
29. Jung R.E., Yeo R.A., Love T.M., Petropoulos H., Sibbitt W.L., Brooks W.M. Biochemical markers of mood: a proton MR spectroscopy study of normal human brain. Biol. Psychiatry. 51:2002;224-229.
30. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
31. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., Bilder R. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry. 49:2001;487-499.
32. Lim K.O., Adalsteinsson E., Spielman D., Sullivan E.V., Rosenbloom M.J., Pferfferbaum A. Proton magnetic resonance imaging of cortical gray and white matter in schizophrenia. Arch. Gen. Psychiatry. 55:1998;346-352.
33. Lindquist D.M., Hawk R.M., Karson C.N., Komoroski R.A. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn. Reson. Med. 43:2000;355-358.
34. 18FDG-PET. Magn. Reson. Med. 43:2000;244-250.
35. Petropoulos H., Brooks W.M., Sibbitt W.L. Jr. Automated T2 quantitation in neuropsychiatric lupus erythematosus: a marker of active disease. J. Magn. Reson. Imaging. 9:1999;39-43.
36. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., Lim K.O. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn. Reson. Med. 41:1999;276-284.
37. Pijnappel W.W.F., van den Boogaart A., de Beer R., van Ormondt D. SVD-based quantification of magnetic resonance signals. J. Magn. Reson. 97:1992;122-134.
38. Rappaport J.L., Giedd J., Kumra S., Jacobsen L., Smith A., Lee P., Nelson J., Hamburger S. Childhood-onset schizophrenia. Progressive ventricular change during adolescence. Arch. Gen. Psychiatry. 54:1997;897-903.
39. Rowland L., Bustillo J., Lauriello J. Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Semin. Clin. Neuropsychiatry. 6:2001;121-130.
40. Saunders D.E., Howe F.A., van den Boogaart A., Griffiths J.R., Brown M.M. Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J. Magn. Reson. Imaging. 9(5):1999;711-716.
41. Selemon L.D., Lidow M.S., Goldman-Rakic P.S. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol. Psychiatry. 46:1999;161-172.
42. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side-effects. Acta Psychiatr. Scand., Suppl. 212:1970;11-19.
43. Soher B.J., Hurd R.E., Sailasuta N., Barker P.B. Quantitation of automated single-voxel proton MRS using cerebral water as an internal reference. Magn. Reson. Med. 36:1996;335-339.
44. Thomas M.A., Ke Y., Levitt J., Caplan R., Curran J., Asarnow R., McCracken J. Preliminary study of frontal lobe 1HMR spectroscopy in childhood-onset schizophrenia. J. Magn. Reson. Imaging. 8:1998;841-846.
45. Van den Boogaart A., Ala-Korpela M., Jokisaari J., Griffiths J.R. Time and frequency domain analysis of NMR data compared: an application to 1-D 1H spectra of lipoproteins. Magn. Reson. Med. 31:1994;347-358.
46. Weiner M.W., Hetherington H., Hubesch B., Karczmar G., Massie B., Maudsley A., Meyerhoff D.J., Sappey-Marinier D., Schaefer S., Twieg D.B. Clinical magnetic resonance spectroscopy of brain, heart, liver, kidney, and cancer. A quantitative approach. NMR Biomed. 2:1989;290-297.
47. Woods B.T. Is schizophrenia a progressive neurodevelopmental disorder? Towards a unitary pathogenetic mechanism. Am. J. Psychiatry. 155:1998;1661-1670.